THE MCMANUS GROUP for AMGEN
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access and reimbursement for Part B and Part D drugs. Advocating for access to biosimilars. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALANNA TEMME | LD, Rep. Jon Porter |
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act. S.1375/H.R.830 - HELP Copays Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALANNA TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.